Mode
Text Size
Log in / Sign up
Phase 2 N=37 Diagnostic

The Role of Contrast Enhanced Ultrasound in Appendicitis

Acute Appendicitis

Enrolled (actual)
37
Serious AEs
0.0%
Results posted
Dec 2022
Primary outcome: Primary: Number of Children With an Accurate Diagnosis of Appendicitis. — 6; 15; 1; 13 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Sulfur hexafluoride lipid-type A microspheres (Drug)
Age
Pediatric · 8+ yrs
Sex
All
Sponsor
Children's Mercy Hospital Kansas City
Primary completion
Mar 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Children With an Accurate Diagnosis of Appendicitis.
6; 15; 1; 13
SECONDARY
Definitive Diagnosis
13
SECONDARY
Number of Participants Who Required Additional CT Scan
SECONDARY
Percentage of Negative Appendectomies
1
SECONDARY
Total Cost Difference Compared to Traditional Ultrasound
16
SECONDARY
Total Cost Difference Between Traditional Ultrasound in Comparison to Costs in CT Scan.
6198

Summary

This study seeks to determine the efficacy of Contrast Enhanced Ultrasound (CEUS) in improving the diagnosis of acute appendicitis in children, when compared to the standard grey-scale ultrasound.

Eligibility Criteria

Inclusion Criteria

  • Present to Children's Mercy Adele Hall campus with a clinical concern for acute appendicitis
  • Age 8 through 17 years
  • seen between Institutional Review Board (IRB) approval date and 12/31/2019
  • Seen Monday- Friday between the hours of 9:00 a.m. and 4:00 pm
  • Has had an IV catheter placed as part of their standard of care

Exclusion Criteria

  • Known cardiac abnormality
  • Pulmonary hypertension
  • Known sensitivity to sulfur hexafluoride, polyethylene glycol 4000, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylglycerol sodium (DPPG-Na), or palmitic acid
  • Does not had an IV catheter placed
  • Unable to roll over
  • Unable to assent
  • Pregnant
  • Lactating
  • Received an ultrasound image from a referring facility
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03687502). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search